Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm Metastasis 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 52Vincristine 32blinatumomab 30Prednisone 27Methotrexate 27Cytarabine 25Dexamethasone 23Specimen Handling 21Rituximab 20Doxorubicin 19merphos 18Mercaptopurine 18Etoposide 18fludarabine 17Biopsy 17prednylidene 16deltacortene 16N,N-dicyclohexyl-isoborneol-10-sulfonamide 16Calcium Dobesilate 16dexamethasone acetate 15dexamethasone 21-phosphate 15auricularum 15Inotuzumab Ozogamicin 15pegaspargase 14azathiopurine 14venetoclax 13Asparaginase 13Spinal Puncture 12Leucovorin 12CT-P10 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × CX 5461 × 1 year × Clear all
NCT07069699 2026-05-13

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

National Cancer Institute (NCI)

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡